Compare JAZZ & ATI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several major end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.